With respect to the planned change of market place of trading from Nasdaq First North Premier to Nasdaq OMX main list, Immunicum AB's Board of Directors has resolved to change the dates for publishing the Company's Year-end report 2015/2016, Annual report 2015/2016 and the Annual General Meeting 2016.
As previously communicated, Immunicum has applied for listing on Nasdaq Stockholm's main market, which is expected to commence by the end of 2016. In order to facilitate the schedule in relation to the exchange and relevant authorities, adjustments to the Company's financial calendar are required. Hence the Year-end report 2015/2016 will be published on August 31st 2016 (previously September 19th 2016), the Annual report 2015/2016 will be published on September 30th 2016 (previously November 7th 2016) and the Annual General Meeting will be held on October 26th 2016 (previously December 1st 2016).
For further information, please contact:
Jamal El-Mosleh, CEO, Immunicum
Phone: +46 (0) 31 41 50 52
jamal.el-mosleh@immunicum.com
The Company's Certified Adviser is Redeye AB
Phone: +46 (0) 8 545 013 31. www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) is working to develop and advance cancer immune primers for the treatment of tumor diseases. A clinical phase II trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST).
For more information, please visit www.immunicum.com